Loading company…
Qiselian develops personalized cell therapy and anti-aging technologies using induced pluripotent stem cell technology.
Founded in 2025 and based in Shanghai, China, Qiselian develops autologous cell therapy, regenerative medicine, and health management products based on induced pluripotent stem cell (iPSC) technology. It closed venture funding from BVCF Capital in April 2025. The company plans to use the funds to build its platform and develop products.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in